Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

In another example of the pharma industry embracing generative artificial intelligence (GenAI), Boehringer Ingelheim ... foundation model technologies – machine learning models that can be ...

Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the company to seek approval for the asset in a second condition. Topline data ...

Administration at the hatchery secures early protection for chicks. With VAXXITEK ® HVT+IBD+H5, Boehringer Ingelheim is expanding its proven VAXXITEK ® range with a new vaccine that protects ...

RIDGEFIELD, Conn., Feb. 20, 2025 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today the appointment of Brian Hilberdink as President, U.S ...